SK282080B6 - Substituované salicylové kyseliny a ich použitie - Google Patents

Substituované salicylové kyseliny a ich použitie Download PDF

Info

Publication number
SK282080B6
SK282080B6 SK547-94A SK54794A SK282080B6 SK 282080 B6 SK282080 B6 SK 282080B6 SK 54794 A SK54794 A SK 54794A SK 282080 B6 SK282080 B6 SK 282080B6
Authority
SK
Slovakia
Prior art keywords
compound
hydroxy
methyl
added
solution
Prior art date
Application number
SK547-94A
Other languages
English (en)
Slovak (sk)
Other versions
SK54794A3 (en
Inventor
Karl Hubert Agback
Leif Ahrgren
Thomas Berglindh
Martin Haraldsson
Lars-Inge Olsson
G�Ran Smedegard
Original Assignee
Pharmacia Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Aktiebolag filed Critical Pharmacia Aktiebolag
Publication of SK54794A3 publication Critical patent/SK54794A3/sk
Publication of SK282080B6 publication Critical patent/SK282080B6/sk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/76Nitrogen atoms to which a second hetero atom is attached
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14Nitrogen atoms
    • C07D261/16Benzene-sulfonamido isoxazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/68Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82Nitrogen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
SK547-94A 1991-11-18 1992-11-04 Substituované salicylové kyseliny a ich použitie SK282080B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9103397A SE9103397D0 (sv) 1991-11-18 1991-11-18 Nya substituerade salicylsyror
PCT/SE1992/000758 WO1993010094A1 (en) 1991-11-18 1992-11-04 Novel substituted salicyclic acids

Publications (2)

Publication Number Publication Date
SK54794A3 SK54794A3 (en) 1995-02-08
SK282080B6 true SK282080B6 (sk) 2001-10-08

Family

ID=20384352

Family Applications (1)

Application Number Title Priority Date Filing Date
SK547-94A SK282080B6 (sk) 1991-11-18 1992-11-04 Substituované salicylové kyseliny a ich použitie

Country Status (29)

Country Link
US (3) US5302718A (sv)
EP (1) EP0613468B1 (sv)
JP (1) JP3259915B2 (sv)
KR (1) KR100253748B1 (sv)
AT (1) ATE194597T1 (sv)
AU (1) AU668528B2 (sv)
CA (1) CA2123697C (sv)
DE (1) DE69231252T2 (sv)
DK (1) DK0613468T3 (sv)
EE (1) EE03026B1 (sv)
ES (1) ES2149780T3 (sv)
FI (1) FI106857B (sv)
GR (1) GR3034585T3 (sv)
HU (2) HU221476B (sv)
IL (1) IL103665A (sv)
LT (1) LT3182B (sv)
LV (1) LV10246B (sv)
MX (1) MX9206647A (sv)
MY (1) MY130169A (sv)
NO (1) NO300805B1 (sv)
NZ (1) NZ244998A (sv)
PT (1) PT101068B (sv)
RU (1) RU2124501C1 (sv)
SE (1) SE9103397D0 (sv)
SK (1) SK282080B6 (sv)
TW (1) TW304944B (sv)
UA (1) UA42869C2 (sv)
WO (1) WO1993010094A1 (sv)
ZA (1) ZA928864B (sv)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
GB9310095D0 (en) * 1993-05-17 1993-06-30 Zeneca Ltd Therapeutic compounds
US5965732A (en) * 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
US5405842A (en) * 1994-01-28 1995-04-11 Silverman; Bernard A. Treatment of steroid dependent asthmatics
GB9504854D0 (en) * 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
WO1997010813A1 (en) 1995-09-18 1997-03-27 Ligand Pharmaceuticals Incorporated Ppar gamma antagonists for treating obesity
JPH09124620A (ja) 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
IL124542A (en) 1996-02-20 2003-07-06 Bristol Myers Squibb Co Method for the preparation of biphenyl isoxazole sulfonamides
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
JP3814742B2 (ja) * 1996-10-18 2006-08-30 イハラケミカル工業株式会社 4−フルオロサリチル酸類
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
AU6187898A (en) * 1997-01-30 1998-08-25 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
GB9804648D0 (en) 1998-03-06 1998-04-29 Zeneca Ltd Chemical compounds
GB9805520D0 (en) 1998-03-17 1998-05-13 Zeneca Ltd Chemical compounds
GB9811427D0 (en) 1998-05-29 1998-07-22 Zeneca Ltd Chemical compounds
WO1999063980A1 (en) 1998-06-12 1999-12-16 Ligand Pharmaceuticals Inc. Treatment of anti-estrogen resistant breast cancer using rxr modulators
KR20020004974A (ko) 1999-03-19 2002-01-16 스티븐 비. 데이비스 비페닐 이속사졸 술폰아미드의 제조방법
NZ517147A (en) 1999-09-04 2003-11-28 Astrazeneca Ab Substituted N-phenyl 2-hydroxy-2-methyl-3,3,3- trifluoropropanamide derivatives which elevate pyruvate dehydrogenase activity
ATE399753T1 (de) 1999-09-04 2008-07-15 Astrazeneca Ab Amide als pyruvatdehydrogenaseinhibitoren
DE60031699T2 (de) 1999-09-04 2007-08-30 Astrazeneca Ab Hydroxyacetamidobenzolsulfonamidderivate
DE60115414D1 (de) * 2000-04-28 2006-01-05 Univ British Columbia N-heterosubstituierten salicylaten zur behandlung von krebs
CA2307278A1 (en) * 2000-04-28 2001-10-28 University Of British Columbia Use of n-heterocyclic substituted salicylic acids for inhibition of cellular uptake of cystine
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
US7732442B2 (en) 2003-09-05 2010-06-08 Ono Pharmaceutical Co., Ltd. Chemokine receptor antagonist and medical use thereof
OA13344A (en) * 2003-12-19 2007-04-13 Pfizer Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-HSD-1) for the treatment of diabetes and obesity.
CA2572119A1 (en) * 2004-06-29 2006-01-12 Warner-Lambert Company Llc Combination therapies utilizing benzamide inhibitors of the p2x7 receptor
GB2421947A (en) * 2005-01-07 2006-07-12 Univ Southampton Sulphonamide compounds for use as inhibitors of NF-kB
CA2643963A1 (en) * 2006-02-21 2007-08-30 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors
AU2009263457B2 (en) * 2008-06-23 2013-05-16 Astellas Pharma Inc. Sulfonamide compounds or salts thereof
AU2012220620A1 (en) * 2011-02-23 2013-10-03 Icahn School Of Medicine At Mount Sinai Inhibitors of bromodomains as modulators of gene expression
SI3300500T1 (sl) 2015-05-20 2020-07-31 Amgen Inc. Triazolni agonisti receptorja APJ
CN108602775B (zh) 2016-01-14 2022-04-29 贝思以色列女会吏医学中心公司 肥大细胞调节剂及其用途
WO2017192485A1 (en) 2016-05-03 2017-11-09 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
WO2018093577A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the apj receptor
US11191762B2 (en) 2016-11-16 2021-12-07 Amgen Inc. Alkyl substituted triazole compounds as agonists of the APJ Receptor
EP3541810B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole phenyl compounds as agonists of the apj receptor
EP3541805B1 (en) 2016-11-16 2020-10-14 Amgen Inc. Heteroaryl-substituted triazoles as apj receptor agonists
WO2018097944A1 (en) 2016-11-16 2018-05-31 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
WO2018093580A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
US11149040B2 (en) 2017-11-03 2021-10-19 Amgen Inc. Fused triazole agonists of the APJ receptor
WO2019213006A1 (en) 2018-05-01 2019-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor
CN111056978B (zh) * 2019-12-13 2021-01-19 西安交通大学 一种磺酰胺类化合物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2396145A (en) * 1940-12-14 1946-03-05 Pharmscia Ab Heterocyclic sulphonamido azo compounds
BE791889A (fr) * 1971-11-26 1973-05-24 Pharmacia Ab Nouveaux derives de la pyridine
US4663334A (en) * 1985-12-11 1987-05-05 Mcneilab, Inc. Heteroaromatic acetylenes useful as antihypertensive agents
US4897397A (en) * 1988-12-16 1990-01-30 Schering Corporation Aryl-alkynoic, alkenoic or alkanoic compounds and compositions useful as antiallergy and anti-inflammatory agents

Also Published As

Publication number Publication date
MX9206647A (es) 1993-05-01
HU221476B (en) 2002-10-28
KR100253748B1 (ko) 2000-05-01
WO1993010094A1 (en) 1993-05-27
FI942289A0 (sv) 1994-05-17
IL103665A (en) 1997-08-14
UA42869C2 (uk) 2001-11-15
LTIP229A (en) 1994-09-25
ATE194597T1 (de) 2000-07-15
IL103665A0 (en) 1993-04-04
US5403930A (en) 1995-04-04
FI942289A (sv) 1994-05-17
DE69231252T2 (de) 2001-03-01
HU211163A9 (en) 1995-10-30
RU2124501C1 (ru) 1999-01-10
AU668528B2 (en) 1996-05-09
LV10246B (en) 1995-04-20
CA2123697C (en) 2003-12-09
SK54794A3 (en) 1995-02-08
NZ244998A (en) 1995-09-26
TW304944B (sv) 1997-05-11
JPH07501330A (ja) 1995-02-09
NO300805B1 (no) 1997-07-28
CA2123697A1 (en) 1993-05-27
EP0613468A1 (en) 1994-09-07
DK0613468T3 (da) 2000-10-23
DE69231252D1 (de) 2000-08-17
ES2149780T3 (es) 2000-11-16
US5302718A (en) 1994-04-12
SE9103397D0 (sv) 1991-11-18
LV10246A (lv) 1994-10-20
GR3034585T3 (en) 2001-01-31
JP3259915B2 (ja) 2002-02-25
AU2958992A (en) 1993-06-15
EE03026B1 (et) 1997-08-15
FI106857B (sv) 2001-04-30
NO941799D0 (no) 1994-05-13
HUT69723A (en) 1995-09-28
LT3182B (en) 1995-03-27
HU9401391D0 (en) 1994-08-29
EP0613468B1 (en) 2000-07-12
NO941799L (sv) 1994-06-22
MY130169A (en) 2007-06-29
PT101068A (pt) 1994-02-28
US5556855A (en) 1996-09-17
ZA928864B (en) 1993-05-13
PT101068B (pt) 1999-08-31

Similar Documents

Publication Publication Date Title
SK282080B6 (sk) Substituované salicylové kyseliny a ich použitie
EP0288973B1 (en) Benzothiazolinone derivatives, their production and pharmaceutical composition
WO2006134467A1 (en) N-(pyridin-2-yl)-sulfonamide derivatives
WO1999062892A1 (en) Aminoazole compounds
EP1828133A2 (en) Methylene inhibitors of matrix metalloproteinase
JPH11269140A (ja) 分化誘導剤
JP2003505367A (ja) マトリックスメタロプロテイナーゼ阻害剤としての3−アリールスルホニル−2−(置換メチル)プロパン酸誘導体
US6727266B2 (en) Substituted tryptophan derivatives
EP0686631A1 (en) Pyrimidine derivatives and pharmaceutical composition
US5232922A (en) Imidazole compounds, processes for their preparation, pharmaceuticals based on these compounds and some intermediates
AU2006319985B2 (en) Acid addition salt of dihydropyridine derivative
CZ287285B6 (cs) Nové substituované salicylové kyseliny
JP2860688B2 (ja) インドール誘導体
JPH09176165A (ja) イミダゾ[1,2−a]ピリジン誘導体、その製法およびその用途
JPH07101941A (ja) 2−[2−(置換アミノ)ベンジルチオ]−5,6, 7,8−テトラヒドロ−4(3h)−キナゾリノン誘 導体
JPH05112559A (ja) 4−アミノ−5−ピリミジンカルボン酸誘導体
JPH05279336A (ja) フェノキシ酢酸誘導体
JPH05262736A (ja) フェノキシ酢酸誘導体
JPH068296B2 (ja) アミノクロマノール誘導体
JPH07119216B2 (ja) ピリジルスルホニル尿素及びピリジルスルホニルチオ尿素の新規な誘導体、それら誘導体の製造法及びそれら誘導体を含有する製剤組成物
JPH05262763A (ja) 2−〔(1h−ベンズイミダゾール−2−イル)スル フィニルメチル〕−4−置換アミノ−5−ピリミジン カルボン酸誘導体
JPH0641051A (ja) フェノキシ酢酸誘導体
JPS63250374A (ja) 〔2−(1,3−ベンゾジオキソ−ル−5−イル)エチル〕チオ誘導体
JPH07330769A (ja) 2−[2−(置換アミノ)ベンジルチオ]−5,6, 7,8−テトラヒドロピリド[4,3−d]ピリミジ ン−4(3H)−オン誘導体
JPH06100541A (ja) ピラゾリノン誘導体